Home > Signaling Pathways>Others>Others 2>Desmopressin acetate trihydrate
Desmopressin acetate trihydrate

This product is for research use only, not for human use. We do not sell to patients.

Desmopressin acetate trihydrate
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
5mg$1203-6 Days
10mg$1803-6 Days
25mg$2793-6 Days
50mg$4153-6 Days
100mg$6193-6 Days
250mg$10803-6 Days
500mg$15503-6 Days
email: [email protected]        [email protected]

Cat #: V3206 CAS #: 62357-86-2 (acetate trihydrate); 16679-58-6 (acetate); free base Purity ≥ 98%

Description: Desmopressin acetate, the acetate salt of desmopressin (also known as DDAVP), is a synthetic octapeptide and an analogue of the human antidiuretic hormone arginine vasopressin. Compare with vasopressin, Desmopressin has improved pharmacokinetics such as prolonged half life and better pharmacodynamics such as higher selectivity for the V2 membrane receptor. Vasopressin is a hormone that reduces the production of urine and desmopressin is a synthetic version for vasopressin. The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. Desmopressin works by limiting the amount of water eliminated in the urine. Desmopressin binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates release of von Willebrand factor from endothelial cells by acting on the V2 receptor. Desmopressin is most frequently prescribed for treatment of diabetes insipidus or nocturnal enuresis.

Top Publications Citing Invivochem Products
Product Catalog 2022
Bulletin Board
Guide to Product Handling
Publications Citing InvivoChem Products
Product Promise
Promise
Molecular Weight (MW)1189.32
Molecular FormulaC48H74N14O17S2
CAS No.62357-86-2 (acetate trihydrate); 16679-58-6 (acetate); free base
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility In VitroDMSO: > 10mM
Water:
Ethanol:
SMILES CodeO=C([C@H]1N(C([C@@H](NC([C@H](CC(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CC2=CC=CC=C2)NC ([C@H](CC3=CC=C(O)C=C3)N4)=O)=O)=O)=O)CSSCCC4=O)=O)CCC1)N[C@H](CCCNC(N)=N)C(NCC (N)=O)=O.CC(O)=O.[H]O[H].[H]O[H].[H]O[H]
SynonymsDDAVP; Adiuretin; Deamino Arginine Vasopressin; Desmogalen; Vasopressin 1-Desamino-8-arginine
ProtocolIn VitroIn vitro activity: Desmopressin (also known as DDAVP) is a synthetic octapeptide and an analogue of the human antidiuretic hormone arginine vasopressin. Vasopressin is a hormone that reduces the production of urine and desmopressin is a synthetic version for vasopressin. The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. Desmopressin works by limiting the amount of water eliminated in the urine. Desmopressin binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates release of von Willebrand factor from endothelial cells by acting on the V2 receptor. Desmopressin is most frequently prescribed for treatment of diabetes insipidus or nocturnal enuresis. Kinase Assay: Cell Assay: HUVECs are transduced with recombinant adenoviruses AdV2R.EGFP (AdV2R) or AdlacZ. 3 days later cells are incubated for 25 min with 1 μM DDAVP or 10 μM forskolin, both in presence of IBMX. Cell extracts are analyzed for eNOS Ser1177 phosphorylation and eNOS expression.
In VivoDDAVP (2 μg/kg) reduces accumulation of ascites and formation of intestinal tumor nodules in mice intraperitoneally inoculated with CT-26 cells. Perioperative administration of DDAVP significantly inhibits tumor progression in animals surgically implanted in the spleen with CT-26 cells, and causes some reduction in liver metastasis. DDAVP is able to inhibit lung colonization by blood-borne breast cancer cells in an experimental murine model. It dramatically reduces lymph node and lung metastasis in a model of mammary tumor manipulation and surgical excision in mice when administered perioperatively, and also exerts antitumor effects in combination with chemotherapy. DDAVP increases the plasma levels of coagulation factor VIII, von Willebrand factor (VWF) and tissue-type plasminogen activator, and also enhances platelet adhesion to the vessel wall.
Animal modelSyngeneic adult male Balb/c mice inoculated with CT-26 colon cancer cells
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM0.8408 mL4.2041 mL8.4082 mL16.8163 mL
5mM0.1682 mL0.8408 mL1.6816 mL3.3633 mL
10mM0.0841 mL0.4204 mL0.8408 mL1.6816 mL
20mM0.0420 mL0.2102 mL0.4204 mL0.8408 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
 
=
Concentration
 
×
Volume
 
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
 
×
 
Volume(start)
V1
 
=
 
Concentration(final)
C2
 
×
 
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O
Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.